Irene A Burger1, Julian Müller2, Olivio F Donati3, Daniela A Ferraro2, Michael Messerli2, Benedikt Kranzbühler4, Edwin E G W Ter Voert2,5, Urs J Muehlematter2, Niels J Rupp6, Ashkan Mortezavi4, Daniel Eberli4. 1. Department of Nuclear Medicine, University Hospital Zürich, Zürich, Switzerland irene.burger@usz.ch. 2. Department of Nuclear Medicine, University Hospital Zürich, Zürich, Switzerland. 3. Institute of Diagnostic and Interventional Radiology, University Hospital Zürich, Zürich, Switzerland. 4. Department of Urology, University Hospital Zürich, Zürich, Switzerland. 5. University of Zurich, Zürich, Switzerland; and. 6. Department of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland.
Abstract
High-intensity focused ultrasound (HIFU) is a promising new modality for the treatment of localized prostate cancer (PCa). Follow-up of patients is recommended with biopsies and multiparametric MRI (mpMRI). However, mpMRI in the postinterventional setting is often false-negative. It was our aim to investigate if the new tracer targeting the prostate-specific membrane antigen (68Ga-PSMA-11) could be used to localize recurrent disease with PET/MR in patients with discrepant findings between mpMRI and template biopsies. Methods: Interim analysis was performed of the first 10 patients scanned between September 2016 and May 2018 with positive template biopsy and negative mpMRI after HIFU from an ongoing clinical trial (NCT02265159). All patients underwent 68Ga-PSMA-11 PET/MRI within 3 mo. Four prostatic quadrants were defined, and for every quadrant suspicion for recurrence was rated on a 5-point Likert scale from definitely no recurrence (1) to highly suspected of recurrence (5), with 4 used as a cutoff for suspected disease based on PET/MRI by a masked reader. 68Ga-PSMA-11 uptake of suspected lesions and background areas was measured with the SUVmax The apparent diffusion coefficient values of lesions and background were given for each segment. PET/MRI scans were compared with the template biopsy results, including corresponding Gleason scores (GS), number of positive cores, and tumor length. Results: The quadrant-based sensitivity, specificity, and positive and negative predictive values for PET/MRI were 55%, 100%, 100%, and 85%, respectively. Patient-based PET/MRI was negative in 4 cases with GS 3 + 4 and a tumor length between 0.1 and 3 mm. All tumor lesions with GS 4 + 3 or higher were detected on PET/MRI. Conclusion: Our preliminary results indicate that 68Ga-PSMA-11-PET/MR has the potential to localize PCa recurrence after HIFU occult on mpMRI.
High-intensity focused ultrasound (HIFU) is a promising new modality for the treatment of localized prostate cancer (PCa). Follow-up of patients is recommended with biopsies and multiparametric MRI (mpMRI). However, mpMRI in the postinterventional setting is often false-negative. It was our aim to investigate if the new tracer targeting the prostate-specific membrane antigen (68Ga-PSMA-11) could be used to localize recurrent disease with PET/MR in patients with discrepant findings between mpMRI and template biopsies. Methods: Interim analysis was performed of the first 10 patients scanned between September 2016 and May 2018 with positive template biopsy and negative mpMRI after HIFU from an ongoing clinical trial (NCT02265159). All patients underwent 68Ga-PSMA-11 PET/MRI within 3 mo. Four prostatic quadrants were defined, and for every quadrant suspicion for recurrence was rated on a 5-point Likert scale from definitely no recurrence (1) to highly suspected of recurrence (5), with 4 used as a cutoff for suspected disease based on PET/MRI by a masked reader. 68Ga-PSMA-11 uptake of suspected lesions and background areas was measured with the SUVmax The apparent diffusion coefficient values of lesions and background were given for each segment. PET/MRI scans were compared with the template biopsy results, including corresponding Gleason scores (GS), number of positive cores, and tumor length. Results: The quadrant-based sensitivity, specificity, and positive and negative predictive values for PET/MRI were 55%, 100%, 100%, and 85%, respectively. Patient-based PET/MRI was negative in 4 cases with GS 3 + 4 and a tumor length between 0.1 and 3 mm. All tumor lesions with GS 4 + 3 or higher were detected on PET/MRI. Conclusion: Our preliminary results indicate that 68Ga-PSMA-11-PET/MR has the potential to localize PCa recurrence after HIFU occult on mpMRI.
Authors: Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter Journal: Am J Nucl Med Mol Imaging Date: 2020-12-15
Authors: Xinrui Zhang; Lisa Landgraf; Nikolaos Bailis; Michael Unger; Thies H Jochimsen; Andreas Melzer Journal: J Nucl Med Date: 2021-06-04 Impact factor: 10.057
Authors: Mariam Aboian; Ramon Barajas; Julia Shatalov; Vahid Ravanfar; Emma Bahroos; Elizabeth Tong; Jennie W Taylor; N Oberheim Bush; Patricia Sneed; Youngho Seo; Soonmee Cha; Miguel Hernandez-Pampaloni Journal: Neurooncol Pract Date: 2020-10-14
Authors: Soleen Ghafoor; Daniel Stocker; Olivio F Donati; Hebert Alberto Vargas; Anton S Becker; Borna K Barth; Daniel Eberli Journal: Abdom Radiol (NY) Date: 2020-11
Authors: Fabian Tollens; Niklas Westhoff; Jost von Hardenberg; Sven Clausen; Michael Ehmann; Frank G Zöllner; Anne Adlung; Dominik F Bauer; Stefan O Schoenberg; Dominik Nörenberg Journal: Radiologe Date: 2021-07-12 Impact factor: 0.635